Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent. Both profit and revenue were in line with Bloomberg estimates
The profit after tax (PAT) grew 68 per cent to Rs 168 crore in the October-December period as against Rs 100 crore in the year-ago period, it stated
The company's pre-sales for the quarter stood at Rs 334 crore, down by 24.61 per cent, year on year (Y-o-Y)
Its revenue from operations climbed 35 per cent to Rs 376.83 crore in the December quarter. The same stood at Rs 279.05 crore a year ago
Revenue from operations declined to Rs 538 crore in the third quarter as compared with Rs 540 crore in the year-ago period
Revenues rose 52.6 per cent to Rs 924.6 crore from Rs 606 crore in October-December 2023-24
However, the Q2 profits were recorded even as the company saw gross revenue decline marginally by 0.7 per cent to Rs 1.66 trillion, down from Rs 1.67 trillion registered in Q3 FY24
The company's disbursements have been slower than its peers in last few quarters. Earlier this month, PNB Housing's reported a 30% rise in disbursements for the third quarter
The company recognised exceptional gains of Rs 5,804 crore over fair-value assessments
MedPlus continued to benefit from strong sales of products under its private label brands in both the pharmaceuticals and consumer wellness categories
VCBL Managing Director Balakrishna Tati announced plans to expand its production capacity by an additional 4,500 metric per annum (TPA), with the new capacity expected to be commissioned by Q4 FY26
The company's PAT, including exceptional items, jumped manifold to Rs 6,026 crore against Rs 187 crore in the October-December period of the preceding 2023-24 financial year
The total income of the company during the quarter increased to Rs 767.92 crore over Rs 624.51 crore in the year-ago period
The bank's net interest income (NII) grew 7.22 per cent Y-o-Y to Rs 11,032 crore in Q3
NII of the lender also declined marginally by 1 per cent Y-o-Y to Rs 5,228 crore
IWL's order book stood at 3,286 MW at the end of the third quarter of the ongoing fiscal year, 28 per cent higher from 2,575 MW in the year-ago period
Revenue from operations rose 10 per cent to Rs 10,907 crore
The bank's provisions and contingencies, or funds set aside to cover loan losses, jumped 87 per cent to Rs 1,744 crore
Marico's expenses rose 17.7 per cent to Rs 2,318 crore ($267.54 million) during the third quarter ended December 31
Sales in India, Sun Pharma's largest revenue-generating region, rose 14 per cent to Rs 4,300 crore, or about 31 per cent of total sales